Shattuck Labs Financial Results Summary
Shattuck Labs, Inc. (STTK), a biotechnology company dedicated to pioneering innovative therapies for inflammatory and immune-mediated diseases, has put forth robust financial results for their latest quarter. Their comprehensive efforts toward the development of novel therapeutics targeting TNF superfamily receptors signify a pivotal advancement in their business strategy and contribute positively to their financial standing.
IND Application and Clinical Trials
Recently, Shattuck Labs submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to evaluate SL-325 in a Phase 1 clinical trial involving healthy participants. The company anticipates receiving clearance for this application in the upcoming quarter. The commencement of trial dosing is planned for Q3 2025, displaying their commitment to advancing critical research in the biotech field.
Clinical Trial Objectives
The Phase 1 clinical trial will primarily focus on assessing the safety, tolerability, immunogenicity, and pharmacokinetics of SL-325. Additionally, the trial aims to determine the recommended Phase 2 dose and dosing schedule for this promising candidate. Subject to regulatory approval, dosing for the first participant in the single ascending dose (SAD) portion is expected to begin soon, with plans to finalize this portion by Q2 2026.
Financial Highlights
As of the end of Q2 2025, Shattuck Labs reported a significant cash balance of approximately $50.5 million. This financial resilience is bolstered by the recent success of their private placement effort, with an anticipated total of about $103 million, after accounting for offering expenses. This funding is envisioned to support their operational needs well into 2029, providing a substantial runway for further development and clinical trials.
Quarterly Financial Overview
The financial results for the quarter highlight substantial research and development investments amounting to $8.7 million, a noticeable decrease compared to the previous year, demonstrating Shattuck's strategic efficiency. General and administrative expenses also witnessed a decrease, coming in at $4.4 million. Despite a net loss of $12.5 million, improvements were noted in comparison to the net loss of $21.6 million recorded in the same quarter the previous year.
Strategic Developments in 2025
Shattuck Labs continues to enrich its portfolio through the development of multiple preclinical DR3-based bispecific antibodies aimed at treating inflammatory bowel disease (IBD) alongside other autoimmune conditions. The nomination of a lead bispecific candidate from their preclinical pipeline is projected for 2025, marking another exciting chapter in their therapeutic development journey.
Participation in Healthcare Conferences
Shattuck Labs has actively engaged in key industry conferences, enhancing visibility for its advancements. CEO Taylor Schreiber delivered presentations at events including the 24th Annual Needham Virtual Healthcare Conference and the Leerink Partners Therapeutics Forum. These platforms enable Shattuck to share insights on their research progress and corporate strategy.
Future Path and Expectations
Looking ahead, Shattuck Labs is poised for a significant presence at the H.C. Wainwright 27th Annual Global Investment Conference. This event will feature a corporate presentation from leadership and opportunities for one-on-one discussions with investors. Shattuck’s road ahead appears optimistic as they gear up for additional Phase 2 clinical trials and continued exploration of funding avenues.
About Shattuck Labs, Inc.
Founded with a commitment to innovate, Shattuck Labs, Inc. specializes in developing first-in-class therapies for patients suffering from inflammatory and immune-mediated diseases. Their continued focus on pioneering drug development is evident in programs such as SL-325, a promising DR3 antagonist antibody targeting established therapeutic pathways. With bases in both Austin and Durham, Shattuck Labs is at the forefront of biotech innovation, aiming to significantly impact patient care in the coming years.
Frequently Asked Questions
What is SL-325?
SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to treat various inflammatory and immune-mediated diseases.
What is the current cash balance of Shattuck Labs?
As of the end of Q2 2025, Shattuck Labs reported a cash balance of approximately $50.5 million.
When is the Phase 1 clinical trial for SL-325 expected to start?
The dosing for the first participant in the Phase 1 clinical trial is anticipated to begin in Q3 2025.
How much funding is expected from the recent private placement?
Shattuck Labs expects to receive about $103 million from their recent oversubscribed private placement, which will support their operations into 2029.
What are the upcoming conferences Shattuck Labs will participate in?
Shattuck Labs plans to attend the H.C. Wainwright 27th Annual Global Investment Conference, where their CEO will present corporate updates and engage in one-on-one meetings.
